<DOC>
	<DOCNO>NCT02164279</DOCNO>
	<brief_summary>About 30 40 % patient suffer type I diabetes risk develop diabetic nephropathy ( DN ) lead less rapidly end-stage renal disease . Nowadays , microalbuminuria often use clinical parameter possible onset DN . However , late ( permit detect renal disease already present ) , non-specific low sensitive biomarker . Therefore main objective study identify early urinary biomarkers predictive DN child type I diabetes , appearance microalbuminuria .</brief_summary>
	<brief_title>Validation Biomarkers Diabetic Nephropathy Type I Diabetic Children</brief_title>
	<detailed_description>Once type I diabetes diagnose , speed progression DN variable . Thus , discovery biomarkers able distinguish progressor patient non-progressor since appearance microalbuminuria , crucial order take care progressor patient earlier slow disease progression . The investigator show urine biological sample extremely well suit proteome analysis aim identify biomarkers renal damage . Indeed , first analyze urinary proteome infant use capillary electrophoresis-coupled mass spectrometry . This technic permit analyse entire urinary proteome person one hour . Several laboratory try identify predictive urinary biomarkers development DN diabetic patient , limited success nowadays clinical practice still use measure microalbuminuria . Contrary precedent study , investigator develop analysis without priori start early sample ( without sign DN ) associate urinary peptide profile DN progression 9-10 year . This nested case-control study cohort 317 patient constitute urinary biological collection . ( The urinary sample type I diabetic cohort 317 patient see 2004 2008 collect . ) These patient contact end 2012 obtain number participation 180 patient authorize use aposteriori urinary sample . Among cohort , investigator evaluate 90 number patient DN define dosage microalbuminuria high 100 mg/L . The primary endpoint study therefore identification urinary biomarkers predictive DN type I diabetes pediatric patient . The secondary endpoint : - The estimation sensibility specificity parameter , Area Under Curve ( AUC ) . - The identification factor associate variability biomarkers expression age moment diagnosis , time diagnosis urinary collection , rate microalbuminuria , type insulin use patient . - And subgroup patient two urinary sample collect , investigator want study urinary proteome stability patient DN 2013 .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<criteria>Patient type I diabetes diagnose 15 yearsold Urinary collection do 5 year diagnosis Urinary collection do without acute intermittent pathology Urinary collection do without treatment ( diabetes treatment ) Glomerular filtration rate â‰¥ 60 mL/min moment urinary collection already do Informed consent obtain aposteriori analysis urinary sample collect 2004 2008 , consent obtain analysis urinary sample collect 2013 Patients suffer autoimmune disease associate diabetes ( vitiligo , Grave 's disease , thyroiditis , pernicious anemia Biermer 's disease ) Patient renal disease ( diabetic nephropathy ) first urinary collection ( 2004 2008 ) Pregnancy , urinary proteome microalbumin dosage modify pregnancy . Patient refusal use urinary sample already collect</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Microalbuminuria</keyword>
	<keyword>diabetic nephropathy</keyword>
	<keyword>type I diabetes</keyword>
	<keyword>early predictive urinary biomarkers</keyword>
</DOC>